blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3280445

EP3280445 - GENE THERAPY TO PREVENT REACTIONS TO ALLERGENS [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  15.12.2023
Database last updated on 03.09.2024
FormerGrant of patent is intended
Status updated on  03.08.2023
FormerExamination is in progress
Status updated on  15.01.2021
FormerRequest for examination was made
Status updated on  12.01.2018
FormerThe international publication has been made
Status updated on  10.11.2017
Most recent event   Tooltip08.08.2024Lapse of the patent in a contracting state
New state(s): SE		published on 11.09.2024 [2024/37]
Applicant(s)For all designated states
Cornell University
Center for Technology Licensing at
Cornell University (CTL)
395 Pine Tree Road, Suite 310
Ithaca, New York 14850 / US
[2023/35]
Former [2018/07]For all designated states
Cornell University
Centre for Technology Licensing at
Cornell University (CTL)
395 Pine Tree Road Suite 310
Ithaca, NY 14850 / US
Inventor(s)01 / CRYSTAL, Ronald G.
435 East 70th Street
Apt. 34-B
New York, New York 10021 / US
02 / PAGOVICH, Odelya E.
1330 First Avenue
New York, New York 10021 / US
03 / CHIUCHIOLO, Maria J.
2501 Porter St NW, Apt 912
Washington, DC 20008 / US
 [2018/36]
Former [2018/07]01 / CRYSTAL, Ronald G.
435 East 70th Street
Apt. 34-B
New York, New York 10021 / US
02 / PAGOVICH, Odelya E.
1330 First Avenue
New York, New York 10021 / US
03 / CHIUCHIOLO, Maria J.
450 East 63rd Street
Apt. 3B
New York, New York 10065 / US
Representative(s)Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[2024/03]
Former [2018/07]Huenges, Martin
Maiwald Patentanwalts GmbH
Elisenhof
Elisenstrasse 3
80335 München / DE
Application number, filing date16777501.411.04.2016
[2018/07]
WO2016US26977
Priority number, dateUS201562145035P09.04.2015         Original published format: US 201562145035 P
US201662314740P29.03.2016         Original published format: US 201662314740 P
[2018/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016164920
Date:13.10.2016
Language:EN
[2016/41]
Type: A1 Application with search report 
No.:EP3280445
Date:14.02.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 13.10.2016 takes the place of the publication of the European patent application.
[2018/07]
Type: B1 Patent specification 
No.:EP3280445
Date:17.01.2024
Language:EN
[2024/03]
Search report(s)International search report - published on:US13.10.2016
(Supplementary) European search report - dispatched on:EP17.04.2019
ClassificationIPC:A61K39/395, C12N15/00
[2018/07]
CPC:
C07K16/4291 (EP,US); A61K48/0066 (US); A01K67/0271 (EP,US);
A01K67/0278 (US); A61K48/0091 (US); A61P37/08 (EP);
C12N15/8509 (US); C12N15/86 (EP,US); A01K2207/12 (EP,US);
A01K2227/105 (EP,US); A01K2267/0387 (EP,US); A61K2039/505 (EP,US);
C07K2317/24 (EP,US); C07K2317/76 (EP,US); C12N2015/8536 (US);
C12N2750/14143 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/07]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:GENTHERAPIE ZUR VERHINDERUNG VON REAKTIONEN AUF ALLERGENE[2018/07]
English:GENE THERAPY TO PREVENT REACTIONS TO ALLERGENS[2018/07]
French:THÉRAPIE GÉNIQUE POUR PRÉVENIR LES RÉACTIONS À DES ALLERGÈNES[2018/07]
Entry into regional phase09.11.2017National basic fee paid 
09.11.2017Search fee paid 
09.11.2017Designation fee(s) paid 
09.11.2017Examination fee paid 
Examination procedure09.11.2017Examination requested  [2018/07]
09.11.2017Date on which the examining division has become responsible
18.11.2019Amendment by applicant (claims and/or description)
15.01.2021Despatch of a communication from the examining division (Time limit: M06)
19.07.2021Reply to a communication from the examining division
17.05.2022Despatch of a communication from the examining division (Time limit: M02)
27.07.2022Reply to a communication from the examining division
04.08.2023Communication of intention to grant the patent
11.12.2023Fee for grant paid
11.12.2023Fee for publishing/printing paid
11.12.2023Receipt of the translation of the claim(s)
Fees paidRenewal fee
27.04.2018Renewal fee patent year 03
29.04.2019Renewal fee patent year 04
27.04.2020Renewal fee patent year 05
27.04.2021Renewal fee patent year 06
27.04.2022Renewal fee patent year 07
27.04.2023Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT17.01.2024
BG17.01.2024
ES17.01.2024
FI17.01.2024
HR17.01.2024
LT17.01.2024
LV17.01.2024
NL17.01.2024
PL17.01.2024
SE17.01.2024
NO17.04.2024
RS17.04.2024
GR18.04.2024
IS17.05.2024
PT17.05.2024
[2024/37]
Former [2024/36]AT17.01.2024
BG17.01.2024
ES17.01.2024
FI17.01.2024
HR17.01.2024
LT17.01.2024
LV17.01.2024
NL17.01.2024
PL17.01.2024
NO17.04.2024
RS17.04.2024
GR18.04.2024
IS17.05.2024
PT17.05.2024
Former [2024/35]AT17.01.2024
BG17.01.2024
ES17.01.2024
FI17.01.2024
HR17.01.2024
LT17.01.2024
NL17.01.2024
NO17.04.2024
RS17.04.2024
GR18.04.2024
IS17.05.2024
Former [2024/34]BG17.01.2024
FI17.01.2024
HR17.01.2024
LT17.01.2024
NL17.01.2024
NO17.04.2024
RS17.04.2024
GR18.04.2024
IS17.05.2024
Former [2024/33]LT17.01.2024
NL17.01.2024
NO17.04.2024
IS17.05.2024
Former [2024/32]NL17.01.2024
IS17.05.2024
Former [2024/31]NL17.01.2024
Documents cited:Search[XYI]WO9901556  (GENENTECH INC [US]) [X] 1-3,5,8,9 * see whole document and in particular paragraph "B. Vectors, Host Cells and recombinant methods" pages 44-49 and Examples 2 and 4.;; sequences 3, 6, 13 * [Y] 6-8 [I] 4,10-14;
 [Y]  - "Mus musculus anti-IgE F(ab)-2 variable heavy chain.", Geneseq, (19990608), Database accession no. AAW95648, URL: EBI, XP002787428 [Y] 6-8 * the whole document *
 [Y]  - "Mus musculus anti-IgE F(ab)-2 variable light chain.", Geneseq, (19990608), Database accession no. AAW95651, URL: EBI, XP002787429 [Y] 6-8 * the whole document *
 [Y]  - "Mus musculus anti-IgE e25 full length variable light chain.", Geneseq, (19990608), Database accession no. AAW95658, URL: EBI, XP002787430 [Y] 6-8 * the whole document *
 [Y]  - CARTON ET AL, "Codon engineering for improved antibody expression in mammalian cells", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, (20070908), vol. 55, no. 2, doi:10.1016/J.PEP.2007.05.017, ISSN 1046-5928, pages 279 - 286, XP022238133 [Y] 6-8 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.pep.2007.05.017
International search[A]US2004229310  (SIMMONS LAURA [US]) [A] 11, 12, (16-19)/(11,12) * para [0044]-[0045] and SEQ ID NOs: 20, 22. *;
 [XY]US2010113361  (MORSEY MOHAMAD A [US], et al) [X] 1-3, 7-9, (16-19)/(1-3,7-9) * para [0024]; [0031]; [0071]; [0077]; [0086]-[0090]; [0097]; [0100] [0104]; [0130]-[0135]; [0146]; [0147]. * [Y] 4-6, 10, (16-19)/(4-6,10-15);
 [A]US2010136030  (SALAH-EDDINE LAMHAMEDI-CHERRADI [US], et al) [A] 11,12,(16-19)/(11,12) * para [0021] and SEQ ID NO: 22. *;
 [A]US2010143262  (VALENTA RUDOLPH [AT], et al) [A] 1* abstract. *;
 [A]US2010189729  (HOERR INGMAR [DE], et al) [A] 13, (16-19)/13 * para [0046] and SEQ ID NOs: 15 and 53. *;
 [XYA]US2011064726  (LIU WAI [GB], et al) [X] 1,14,15 * para [0006]; [0004]; [0114]; [0174]; [0374]; [0413]. * [Y] (16-19)/(14,15) [A] 11-13, (16-19)/(11-13);
 [Y]US2011065779  (FANG JIANMIN [US], et al) [Y] 10,(16-19)/10 * para [0013]; [0123]-[0125]. *;
 [A]US2012258107  (GRAVERSEN NIELS JONAS HEILSKOV [DK], et al) [A] 11,12, (16-19)/(11,12) * para [0588]; SEQ ID NO: 81. *;
 [A]US2013058936  (BRUENKER PETER [CH], et al) [A] 11,12,(16-19)/(11,12) * para [0220] and SEQ ID NO: 45 *;
 [A]US2013236467  (GRIGGS JEREMY [GB], et al) [A] 11,12,(16-19)/(11,12) * Table 5 and SEQ ID NO: 99. *;
 [Y]US2014336245  (MINGOZZI FEDERICO [FR], et al) [Y] 4-6 and (16-19)/(4-6) * para [0011]-[0018]. *
by applicantUS4797368
 US4863457
 US5378475
 US5443505
 US5464758
 US5814618
 WO9901556
 US6342390
 US6682735
 US6723551
 US6821511
 US7112715
 US2011064726
    - IM et al., Cell,, (19900000), vol. 61, pages 447 - 57
    - CHIORINI et al., J. Virol., (19970000), vol. 71, pages 6823 - 1088
    - CEARLEY et al., Molecular Therapy, (20060000), vol. 13, no. 3, pages 528 - 537
    - CARTER, B.J., Hum. Gene Ther., (20050000), vol. 16, pages 541 - 550
    - SRIVASTAVA et al., J. Virol., (19830000), vol. 45, pages 555 - 64
    - BANTEL-SCHAAL et al., J. Virol., (19990000), vol. 73, no. 2, pages 1309 - 1319
    - RUTLEDGE et al., J. Virol., (19980000), vol. 72, pages 309 - 319
    - WU et al., J. Virol., (20000000), vol. 74, pages 8635 - 47
    - DE et al., Mol. Ther., (20060000), vol. 13, no. 1, pages 77 - 87
    - GAO et al., J. Virol., (20040000), vol. 78, pages 6381 - 6388
    - GAO et al., Proc. Natl. Acad. Sci. USA, (20020000), vol. 99, pages 11854 - 11859
    - WATANABE et al., Gene Ther., (20100000), vol. 77, no. 8, pages 1042 - 1051
    - MAO et al., Hum. Gene Therapy, (20110000), vol. 22, pages 1525 - 1535
    - NO et al., Proc. Natl. Acad. Sci., (19960000), vol. 93, pages 3346 - 3351
    - INDRA et al., Nuc. Acid. Res., (19990000), vol. 27, pages 4324 - 4327
    - KRAMERFUSSENEGGER, Methods Mol. Biol., (20050000), vol. 308, pages 123 - 144
    - HOLLIGER et al., Nat. Biotech., (20050000), vol. 23, no. 9, pages 1126 - 1129
    - KOHLERMILSTEIN, Eur. J. Immunol., (19760000), vol. 5, pages 511 - 519
    - LONBERG, Nat. Biotechnol., (20050000), vol. 23, no. 9, pages 1117 - 25
    - LONBERG, Handb. Exp. Pharmacol., (20080000), vol. 181, pages 69 - 97
    - "Gene Expression Technology", GOEDDEL, Methods in Enzymology, Academic Press, San Diego, (19900000), vol. 185
    - NIWA et al., Gene, (19910000), vol. 108, pages 193 - 199
    - DALY et al., Proc. Natl. Acad. Sci. U.S.A., (19990000), vol. 96, pages 2296 - 2300
    - SONDHI et al., Mo/. Ther., (20070000), vol. 15, pages 481 - 491
    - WRIGHT et al., Curr. Opin. Drug Discov. Devel., (20030000), vol. 6, no. 2, pages 174 - 178
    - WRIGHT et al., Molecular Therapy, (20050000), vol. 12, pages 171 - 178
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.